AstraZeneca bypasses insurance - again – to make new hypertension combo compete with generics
This article was originally published in Scrip
After its first "direct-to-patients" sales programme in February for an off-patent breast cancer drug, AstraZeneca has rolled out a second similar scheme, this time for a combination product never before marketed – the hypertension drug Dutoprol (metroprolol succinate extended release/HCTZ) tablets. Under "Dutoprol Direct", patients pay out-of-pocket and bypass health insurance but can have three month's supply delivered direct to their home from a pharmacy benefits management company for $55.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.